Finerenone in Persons with Chronic Kidney Disease without Diabetes

AI Insight

This study evaluated finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in patients with chronic kidney disease who do not have diabetes. The research examined whether finerenone could slow kidney disease progression and reduce cardiovascular events in this patient population. The trial assessed clinical outcomes including kidney failure, sustained decrease in estimated glomerular filtration rate, and cardiovascular death or hospitalization.

Why it matters

Chronic kidney disease affects millions globally, and treatment options for non-diabetic patients remain limited compared to those with diabetes. If effective, finerenone could provide a new therapeutic approach for slowing kidney disease progression in a large patient population currently lacking targeted interventions.